vs

Side-by-side financial comparison of MAXCYTE, INC. (MXCT) and Twin Vee PowerCats, Co. (VEEE). Click either name above to swap in a different company.

MAXCYTE, INC. is the larger business by last-quarter revenue ($4.8M vs $3.0M, roughly 1.6× Twin Vee PowerCats, Co.). Twin Vee PowerCats, Co. runs the higher net margin — -85.6% vs -200.5%, a 114.8% gap on every dollar of revenue. On growth, Twin Vee PowerCats, Co. posted the faster year-over-year revenue change (60.4% vs -20.9%). Twin Vee PowerCats, Co. produced more free cash flow last quarter ($-1.9M vs $-2.9M). Over the past eight quarters, MAXCYTE, INC.'s revenue compounded faster (-7.4% CAGR vs -24.3%).

MaxCyte Inc. is a global biotechnology company focused on developing cell engineering platforms and enabling technologies for cell and gene therapy advancement. Its proprietary non-viral cell modification systems are widely used by pharmaceutical, biotech and life science research entities to develop immunotherapies, gene-edited treatments and next-generation biologic drugs from preclinical research through commercialization.

Twin Vee PowerCats Co. is a leading manufacturer of high-performance recreational power catamaran boats. The company offers a diverse lineup of catamaran models suited for leisure cruising, fishing, water sports, and commercial marine use, serving customers primarily across North America, with a growing distribution network in global coastal markets.

MXCT vs VEEE — Head-to-Head

Bigger by revenue
MXCT
MXCT
1.6× larger
MXCT
$4.8M
$3.0M
VEEE
Growing faster (revenue YoY)
VEEE
VEEE
+81.3% gap
VEEE
60.4%
-20.9%
MXCT
Higher net margin
VEEE
VEEE
114.8% more per $
VEEE
-85.6%
-200.5%
MXCT
More free cash flow
VEEE
VEEE
$1.0M more FCF
VEEE
$-1.9M
$-2.9M
MXCT
Faster 2-yr revenue CAGR
MXCT
MXCT
Annualised
MXCT
-7.4%
-24.3%
VEEE

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
MXCT
MXCT
VEEE
VEEE
Revenue
$4.8M
$3.0M
Net Profit
$-9.6M
$-2.6M
Gross Margin
3.7%
Operating Margin
-234.5%
-87.7%
Net Margin
-200.5%
-85.6%
Revenue YoY
-20.9%
60.4%
Net Profit YoY
9.4%
-119.0%
EPS (diluted)
$-1.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MXCT
MXCT
VEEE
VEEE
Q4 25
$4.8M
$3.0M
Q3 25
$4.6M
$3.4M
Q2 25
$5.8M
$4.8M
Q1 25
$5.7M
$3.6M
Q4 24
$6.1M
$1.9M
Q3 24
$5.6M
$2.9M
Q2 24
$5.0M
$4.3M
Q1 24
$5.6M
$5.3M
Net Profit
MXCT
MXCT
VEEE
VEEE
Q4 25
$-9.6M
$-2.6M
Q3 25
$-12.4M
$-2.8M
Q2 25
$-12.4M
$-1.7M
Q1 25
$-10.3M
$-1.6M
Q4 24
$-10.6M
$-1.2M
Q3 24
$-11.6M
$-3.0M
Q2 24
$-9.4M
$-4.5M
Q1 24
$-9.5M
$-2.3M
Gross Margin
MXCT
MXCT
VEEE
VEEE
Q4 25
3.7%
Q3 25
-1.3%
Q2 25
13.8%
Q1 25
14.9%
Q4 24
-57.6%
Q3 24
-5.0%
Q2 24
4.7%
Q1 24
5.3%
Operating Margin
MXCT
MXCT
VEEE
VEEE
Q4 25
-234.5%
-87.7%
Q3 25
-307.4%
-81.0%
Q2 25
-244.3%
-35.2%
Q1 25
-214.1%
-46.5%
Q4 24
-213.1%
-224.9%
Q3 24
-250.4%
-107.3%
Q2 24
-241.0%
-107.7%
Q1 24
-219.8%
-48.2%
Net Margin
MXCT
MXCT
VEEE
VEEE
Q4 25
-200.5%
-85.6%
Q3 25
-269.7%
-80.4%
Q2 25
-212.2%
-34.8%
Q1 25
-178.7%
-44.6%
Q4 24
-175.0%
-62.7%
Q3 24
-205.9%
-103.7%
Q2 24
-188.8%
-104.4%
Q1 24
-170.6%
-44.3%
EPS (diluted)
MXCT
MXCT
VEEE
VEEE
Q4 25
$-1.19
Q3 25
$-0.12
$-1.23
Q2 25
$-0.12
$-0.87
Q1 25
$-1.08
Q4 24
$-3.51
Q3 24
$-0.11
$-2.64
Q2 24
$-0.09
$-3.09
Q1 24
$-1.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MXCT
MXCT
VEEE
VEEE
Cash + ST InvestmentsLiquidity on hand
$103.0M
$1.4M
Total DebtLower is stronger
$499.9K
Stockholders' EquityBook value
$171.5M
$13.5M
Total Assets
$202.5M
$16.2M
Debt / EquityLower = less leverage
0.04×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MXCT
MXCT
VEEE
VEEE
Q4 25
$103.0M
$1.4M
Q3 25
$105.7M
$2.7M
Q2 25
$126.6M
$6.0M
Q1 25
$138.3M
$4.9M
Q4 24
$154.5M
$7.5M
Q3 24
$153.8M
$11.1M
Q2 24
$157.3M
$14.9M
Q1 24
$157.5M
$17.1M
Total Debt
MXCT
MXCT
VEEE
VEEE
Q4 25
$499.9K
Q3 25
$499.9K
Q2 25
$499.9K
Q1 25
$499.9K
Q4 24
$499.9K
Q3 24
$499.9K
Q2 24
$499.9K
Q1 24
$499.9K
Stockholders' Equity
MXCT
MXCT
VEEE
VEEE
Q4 25
$171.5M
$13.5M
Q3 25
$180.3M
$15.9M
Q2 25
$190.7M
$18.6M
Q1 25
$199.4M
$17.7M
Q4 24
$206.3M
$19.2M
Q3 24
$213.3M
$17.4M
Q2 24
$221.3M
$19.6M
Q1 24
$226.4M
$22.3M
Total Assets
MXCT
MXCT
VEEE
VEEE
Q4 25
$202.5M
$16.2M
Q3 25
$213.5M
$18.9M
Q2 25
$219.8M
$22.4M
Q1 25
$230.0M
$23.6M
Q4 24
$239.5M
$25.9M
Q3 24
$248.6M
$30.1M
Q2 24
$251.5M
$33.8M
Q1 24
$257.9M
$36.5M
Debt / Equity
MXCT
MXCT
VEEE
VEEE
Q4 25
0.04×
Q3 25
0.03×
Q2 25
0.03×
Q1 25
0.03×
Q4 24
0.03×
Q3 24
0.03×
Q2 24
0.03×
Q1 24
0.02×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MXCT
MXCT
VEEE
VEEE
Operating Cash FlowLast quarter
$-2.7M
$-1.7M
Free Cash FlowOCF − Capex
$-2.9M
$-1.9M
FCF MarginFCF / Revenue
-61.0%
-62.5%
Capex IntensityCapex / Revenue
4.8%
4.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-36.2M
$-9.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MXCT
MXCT
VEEE
VEEE
Q4 25
$-2.7M
$-1.7M
Q3 25
$-7.5M
$-2.6M
Q2 25
$-9.9M
$-745.6K
Q1 25
$-14.4M
$-1.7M
Q4 24
$-7.8M
$-2.3M
Q3 24
$-4.4M
$-2.4M
Q2 24
$-4.8M
$-482.1K
Q1 24
$-10.6M
$-1.7M
Free Cash Flow
MXCT
MXCT
VEEE
VEEE
Q4 25
$-2.9M
$-1.9M
Q3 25
$-7.8M
$-3.1M
Q2 25
$-10.4M
$-1.5M
Q1 25
$-15.1M
$-2.6M
Q4 24
$-8.0M
$-3.6M
Q3 24
$-4.8M
$-3.7M
Q2 24
$-5.1M
$-2.2M
Q1 24
$-11.4M
$-3.7M
FCF Margin
MXCT
MXCT
VEEE
VEEE
Q4 25
-61.0%
-62.5%
Q3 25
-168.5%
-91.2%
Q2 25
-179.2%
-30.6%
Q1 25
-262.3%
-71.0%
Q4 24
-131.6%
-192.8%
Q3 24
-85.5%
-128.8%
Q2 24
-103.3%
-51.0%
Q1 24
-203.6%
-70.9%
Capex Intensity
MXCT
MXCT
VEEE
VEEE
Q4 25
4.8%
4.6%
Q3 25
6.5%
14.0%
Q2 25
10.0%
14.9%
Q1 25
11.4%
22.9%
Q4 24
2.4%
68.8%
Q3 24
7.2%
45.8%
Q2 24
5.9%
39.9%
Q1 24
14.4%
37.7%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MXCT
MXCT

Products$4.2M87%
Other$634.0K13%

VEEE
VEEE

Segment breakdown not available.

Related Comparisons